Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease. Issue 1 (23rd January 2023)

• Record Type: Journal Article
• Authors: Niitsu, Takayuki; Fukushima, Kiyoharu; Komukai, Sho; Takata, So; Abe, Yuko; Nii, Takuro; Kuge, Tomoki; Iwakoshi, Shinichi; Shiroyama, Takayuki; Miyake, Kotaro; Tujino, Kazuyuki; Tanizaki, Satoshi; Iwahori, Kota; Hirata, Haruhiko; Miki, Keisuke; Yanagawa, Masahiro; Takeuchi, Noriyuki; Takeda, Yoshito; Kida, Hiroshi; Kumanogoh, Atsushi
• Is Part Of: RMD open. Volume 9:Issue 1(2023)
• Publication Date: 2023-01-23
• Subjects: pulmonary fibrosis -- therapeutics -- fibroblasts; Musculoskeletal system -- Diseases -- Periodicals; Rheumatism -- Periodicals; 616.7005
• DOI: 10.1136/rmdopen-2022-002667
• Languages: English
• ISSNs: 2056-5933

Abstract

Abstract : Objective: No studies have demonstrated the real-world efficacy of antifibrotics for progressive fibrosing interstitial lung disease (PF-ILD). Therefore, we evaluated the efficacy of antifibrotics in patients with PF-ILD. Methods: We retrospectively reviewed the medical records of patients with ILD from January 2012 to July 2021. Patients were diagnosed with PF-ILD if they had ≥10% fibrosis on high-resolution CT (HRCT) and a relative forced vital capacity (FVC) decline of either ≥10% or >5% to <10% with clinical deterioration or progression of fibrosis on HRCT during overlapping windows of 2 years and with a %FVC of ≥45%. We compared FVC changes and overall survival (OS) between patients with and without antifibrotics. FVC changes were analysed using generalised estimating equations. We used inverse probability weighting (IPW) and statistical matching to adjust for covariates. Results: Of the 574 patients, 167 were diagnosed with PF-ILD (idiopathic pulmonary fibrosis (IPF), n=64; non-IPF, n=103). Antifibrotics improved the FVC decline in both IPF (p=0.002) and non-IPF (p=0.05) (IPW: IPF, p=0.015; non-IPF, p=0.031). Among patients with IPF, OS was longer in the antifibrotic group (log-rank p=0.001). However, among patients with non-IPF, OS was not longer in the antifibrotic group (p=0.3263) (IPW and statistical matching: IPF, p=0.0534 and p=0.0018; non-IPF, p=0.5663 and p=0.5618). Conclusion: This is the first real-world study to show that antifibrotics improve the FVC decline in PF-ILD. However, among patients with non-IPF, we found no significant difference in mortality between those with and without antifibrotics. Future studies must clarify whether antifibrotics improve the prognosis of non-IPF.